Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
ISO accreditation acquired for MammaPrint breast cancer risk test
October 6th, 2005
Agendia has been granted the ISO 17025 accreditation for its MammaPrint service, carried out at the company's laboratory facilities in Amsterdam, The Netherlands. MammaPrint is a gene expression service that assesses the risk of metastasis (cancerous spread) in breast cancer patients. Agendia is the first company worldwide to be granted ISO accreditation for a microarray-based diagnostic test. The ISO 17025 is an international standard for the competence of testing laboratories and one of the strictest to date. This accreditation is granted for 4 years, however the Dutch Accreditation Council will perform yearly inspections of the Agendia laboratory...
Source: Women's Health Weekly (2005-10-06)
|
